LionBio Therapeutics raises $6M pre seed
Announced 7 November 2026
◆ The Round
LionBio Therapeutics raised $6M in pre seed funding, announced on 7 November 2026, led by South Park Commons. The round is tracked live by Fusion42 as part of the Raise fund database and the Scout startup database.
◆ About LionBio Therapeutics
Biotech startup developing nanoparticle-encapsulated nasal GLP-1 delivery technology, starting with intranasal semaglutide. LionBio Therapeutics is based in United States and currently at pre seed stage, operating in Biotech.
◆ Investors
LeadSouth Park Commons
◆ Market context
This funding event is a citable node in Fusion42's market graph: it links LionBio Therapeutics's Scout profile to the funds behind the round and to related Wire analysis, and is refreshed from public announcements as the round is confirmed or extended. It is the same live market data Arthur reasons over when benchmarking a founder's own raise against what is closing in the market right now.
◆ Explore the market
◆ FAQ
How much did LionBio Therapeutics raise?
LionBio Therapeutics raised $6M in its pre-seed round, announced 2026-11-07.
Who invested in LionBio Therapeutics's pre-seed round?
The round was led by South Park Commons.
What does LionBio Therapeutics do?
Biotech startup developing nanoparticle-encapsulated nasal GLP-1 delivery technology, starting with intranasal semaglutide.
Verified 6 November 2026 · Sources: public filings